Extracellular matrix-derived angiogenic factor(s) inhibit endothelial cell proliferation, enhance differentiation, and stimulate angiogenesis in vivo

被引:0
作者
Akhtar, N
Carlson, S
Pesarini, A
Ambulos, N
Passaniti, A
机构
[1] Univ Maryland, Sch Med, Dept Pathol, Baltimore, MD 21201 USA
[2] Greenebaum Canc Ctr, Baltimore, MD 21201 USA
来源
ENDOTHELIUM-NEW YORK | 2001年 / 8卷 / 03期
关键词
angiogenesis; endothelial cells; matrix; proliferation;
D O I
暂无
中图分类号
Q2 [细胞生物学];
学科分类号
071009 ; 090102 ;
摘要
To isolate matrix molecules with angiogenic activity, tumor extracellular matrix (ECM) fractions from the basement membrane preparation Matrigel were analyzed for effects on endothelial cell (EC) proliferation, differentiation, and vessel formation in giro. Inhibition of human and bovine EC DNA synthesis was evident upon treatment with several soluble Matrigel fractions including conditioned media (MGCM). After size fractionation of MGCM, EC growth arrest was activated by factor(s) smaller than 3,000 daltons (3KF). Bovine EC differentiation (tube formation) was promoted by both MGCM and 3KF fractions in two different models using matrigel or collagen gels to stimulate tube formation. The 3KF factor(s) stimulated angiogenesis when implanted in the cornea or subcutaneously in mice. FGF-induced angiogenesis and blood flow were increased in the presence of 3KF factor(s), an effect that was inhibited by the anti-angiogenic molecule endostatin. Further characterization of the low molecular weight 3KF samples by RP-HPLC revealed several fractions exhibiting EC growth arrest activity. These results suggest that the ability of ECM preparations to induce EC growth arrest and tube formation may reside, at least partially, in previously undetected low molecular weight molecules. Characterization of these ECM-associated inhibitors may lead to the development of novel anti-angiogenic and anti-tumor compounds.
引用
收藏
页码:221 / 234
页数:14
相关论文
共 40 条
[1]   MATRIGEL PROMOTES RETINOBLASTOMA CELL-GROWTH INVITRO AND INVIVO [J].
ALBINI, A ;
MELCHIORI, A ;
GAROFALO, A ;
NOONAN, DM ;
BASOLO, F ;
TARABOLETTI, G ;
CHADER, GJ ;
GIAVAZZI, R .
INTERNATIONAL JOURNAL OF CANCER, 1992, 52 (02) :234-240
[2]   Angiogenesis assays: Problems and pitfalls [J].
Auerbach, R ;
Akhtar, N ;
Lewis, RL ;
Shinners, BL .
CANCER AND METASTASIS REVIEWS, 2000, 19 (1-2) :167-172
[3]   The hemostatic system as a regulator of angiogenesis [J].
Browder, T ;
Folkman, J ;
Pirie-Shepherd, S .
JOURNAL OF BIOLOGICAL CHEMISTRY, 2000, 275 (03) :1521-1524
[4]  
Colorado PC, 2000, CANCER RES, V60, P2520
[5]  
DVORAK HF, 1995, AM J PATHOL, V146, P1029
[6]   ANGIOGENESIS IN CANCER, VASCULAR, RHEUMATOID AND OTHER DISEASE [J].
FOLKMAN, J .
NATURE MEDICINE, 1995, 1 (01) :27-31
[7]  
Grant D S, 1997, EXS, V79, P317
[8]  
Grant D S, 1995, EXS, V74, P235
[9]   Quantitative angiogenesis assays: Progress and problems [J].
Jain, RK ;
Schlenger, K ;
Hockel, M ;
Yuan, F .
NATURE MEDICINE, 1997, 3 (11) :1203-1208
[10]   Canstatin, a novel matrix-derived inhibitor of angiogenesis and tumor growth [J].
Kamphaus, GD ;
Colorado, PC ;
Panka, DJ ;
Hopfer, H ;
Ramchandran, R ;
Torre, A ;
Maeshima, Y ;
Mier, JW ;
Sukhatme, VP ;
Kalluri, R .
JOURNAL OF BIOLOGICAL CHEMISTRY, 2000, 275 (02) :1209-1215